Full-Time

Manager – Global Regulatory Affairs

Marketed Products

Posted on 3/13/2025

Takeda

Takeda

10,001+ employees

Develops and commercializes biopharmaceuticals and vaccines

Compensation Overview

$180k - $246kAnnually

Mid, Senior

Cambridge, MA, USA + 1 more

More locations: Boston, MA, USA

Up to 75% remote work is allowed; up to 30% domestic travel required.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Bachelor’s degree in Pharmacy, Pharmaceutical Sciences, Chemistry, Biology or related field
  • 4 years of prior experience
  • Prior experience must include: Regulatory submissions to US FDA, EU, and other international health authorities
  • Manage the authoring, review cycles, finalization, and submission of a Fast Track Designation Request to the US FDA and Orphan Drug Designation request to the EMA
  • Oversee and manage all Regulatory activities related to ongoing clinical trials and ensure compliance with applicable regulations
  • Author and manage review cycles for nonclinical regulatory content in submissions like Initial IBs and subsequent updates, briefing books, DSURs, Annual Reports, CTN, IND, CTA, PSP, PIP, 15-day safety notifications, and rapid response document
  • Submission planning and management of Regulatory submissions
  • Collaborate with cross-functional team members like Clinical Science, Safety, DSRE, DMPK, Clinical and nonclinical Pharmacology, Regulatory Operations, Publishing, and external teams as needed to ensure timely submissions to Health Authorities
  • Initiate reviews of regulatory documents, ensure cross-functional team engagement, and conduct comment resolution meetings for timely resolution of comments
  • Perform regulatory analysis, competitor product research, and Probability of Regulatory Success (PRS) exercise for assigned products
  • Provide end-user support for Regulatory electronic document management system (EDMS)
  • Create job aids to simplify existing processes and improve adoption of those processes
  • Represent Regulatory team on business development activities as needed.
Responsibilities
  • Assist the Global Regulatory Lead (GRL) and is accountable for working with regulatory regional leads, other functions and vendors to ensure global regulatory submissions are provided to local Takeda affiliates in compliance with local regulations and to maintain compliance for products
  • In collaboration with GRL lead less complex multi-function submissions or support GRLs for more complex submissions
  • Provide strategic and tactical guidance to teams, including regulatory review of clinical trial documents and collaborates cross functionally to ensure the global regulatory strategy is updated and executed, ensuring global regulatory compliance
  • Assist the Global Regulatory Lead with Health Authority meetings and responses
  • Partner with functions responsible for ensuring market access and regional GRA leads to understand market access topics and strategize opportunities to strengthen product development plan(s) and build into global integrated regulatory strategy.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines. The company invests heavily in research and development to create new molecular entities (NMEs) and commercialize them, with a goal of launching up to 15 new products by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to provide life-changing therapies while ensuring that patient needs are prioritized and environmental risks are managed.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's collaboration with BridGene could enhance its immunology and neurology offerings.
  • The SEA AtM Summit highlights Takeda's commitment to expanding access to medicines in Asia.
  • Positive Phase III trial results for a cancer drug strengthen Takeda's oncology portfolio.

What critics are saying

  • Antitrust litigation in the US could impact Takeda's market position and reputation.
  • The $770 million deal with BridGene poses financial risks if outcomes aren't met.
  • Geopolitical risks could disrupt Takeda's global operations and supply chain.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and innovations.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Nyasa Times
Feb 6th, 2025
Forgotten Children: Mzimba's Tukuyu CBCC Struggles to Provide Basic Education

VillageReach, in partnership with Takeda Pharmaceutical Company Limited, has launched a new initiative aimed at strengthening health systems and improving...